Next Generation Cancer Diagnostics and Monitoring Technologies
Imagine the potential of diagnostics enabling personalized cancer care
Welcome Evelina, Sandra and Francisco
We are pleased to welcome Dr. Evelina Blomberg, Dr. Sandra Freiberger-Rupp and Dr. Francisco Garcia Ascencio to our team. They all have a scientific background in cancer research and bring many years of work experience in routine diagnostics, assay development or clinical trial design and management to our interdisciplinary and international R&D team. We look forward to working with them to reach our goal of enabling personalized cancer care.Read more
Oncobit at BiotechX and MEDICA
Oncobit presented its cancer-type specific diagnostic and monitoring solutions to the MedTech community. For the first time Oncobit took part in the BiotechX, Europe’s largest congress covering diagnostics, precision medicine and digital transformation, as well as the MEDICA, world's largest medical trade fair for medical technology, diagnostics and pharmaceuticals.Read more
We are thrilled to announce that Dr. Bjoern Biedermann has joined our team as Chief Business Officer! Bjoern has more than 12 years of experience in the life science and diagnostic industry, in both international corporations and start-ups. With his expertise in sales, marketing, business development and customer support, Bjoern will coordinate all of Oncobit's commercialization activities.
Oncobit receives prestigious Innosuisse certificate
We are proud to announce that we obtained the prestigious Innosuisse Certificate, awarded to Swiss Startups ready for sustainable growth! We would also like to take this opportunity to thank Innosuisse for their continuous support!Read more
Oncobit CE marks its first products
Oncobit has CE marked its first product to enable personalized cancer care. Oncobit PM BRAFV600 allows the sensitive and specific detection of BRAFV600 mutations in the patient’s blood over time and can be utilized for the monitoring of treatment response, minimal residual disease, and disease recurrence of melanoma.Read more
We are very excited that Hiro Yamada joined our team in May as a Research Associate. Hiro has worked for 10 years as research coordinator and lab manger in the US and Switzerland and will strengthen our laboratory team with his extensive expertise in biochemistry and molecular biology techniques.
Oncobit is part of the Swiss National Startup Team 2022
We are thrilled to be one of ten Venture Leaders Medtech 2022. During the kick-off event, our CEO Claudia Scheckel was selected to serve as team captain during the roadshow in Boston in June 2022.Read more
Oncobit obtains ISO 13485 certification
Oncobit obtains ISO 13485 certification for the design, development and manufacturing of IVD systems to detect and monitor genomic alterations in cancer patients. The certification of Oncobit's quality management system is a major milestone and critical for the launch of Oncobit's products on the European market.Read more
Oncobit wins Venture Kick
By passing the third stage of Venture Kick, Oncobit receives 150'000 CHF to advance personalized cancer care.Read more
Oncobit Team Expansion
Dr. Elisa Bellini as Senior Scientist and Dr. Barbara Geissmann as Senior Computer Scientist officially join the Oncobit team. Both are experts in their respective fields, and previously worked closely with Oncobit through an Innosuisse project.
Oncobit passes Second Stage of Venture Kick
Oncobit successfully passes the second stage of Venture Kick and wins CHF 40’000.
Reinforcement of Team and Relocation of Oncobit Offices
Oncobit moves into its own offices in Schlieren and expands its software team by welcoming Lucas Kohler, joining from ETH, where he obtained a Master in Statistics, as well as Dr. Stephany Orjuela, who just completed her PhD in bioinformatics.
Oncobit Closes CHF 2.3 million Seed Financing Round
The MedTech startup based in Zurich secures more than CHF 2.3 million in seed financing. With Dr. Simona Morello (Business Developer) and Dr. Elena Clementi (Product Developer) two new specialists will strengthen the Oncobit team to further develop its products and obtain regulatory approval.Read more
Oncobit Attends Prestigious Innosuisse Market Validation Camp
Oncobit is part of the Innosuisse internalisation camp spring cohort, to move forward with market validation in the US.
Oncobit Passes First Stage of Venture Kick
Oncobit successfully passes the first stage of Venture Kick and wins CHF 10’000.
Oncobit Receives USZ Health Innovation Hub Support
Oncobit is accepted into the innovation program of the Health Innovation Hub from the University Hospital Zurich and receives CHF 200’000.
Oncobit Ranks in the Top-5 of the Swiss AI Award
Oncobit is selected to be under the Top-5 of the first Swiss AI Award.
Oncobit’s tests provide critical decision support in the treatment and monitoring of advanced melanoma patients.
Prof. Dr. med. Reinhard Dummer, Department of Dermatology USZ, Head of the Skin tumor center, Expert for the Comprehensive Cancer Center Zürich